Who invested in Aktis Oncology

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$175Mraised across 1 round since 2024, from 1 source

Latest round: Series B, $175MSept 2024
Investors: 5

See who backed them

The rounds

Sept 2024
Series B$175M
Source recordedSEC filing: $175M sold, first sale Sept 2024

Founders and team

From Aktis Oncology's own website: 1 founder, 9 on the team.

Todd FoleyCo-founder and Chairman

Dana KennedySenior Vice President
Kyle KuvalankaChief Financial Officer
Mary ThistleIndependent Director
Mike ShermanIndependent Director
Carlos RodriguezTeam
Karen McCarthyTeam
Lorraine HorganTeam
Nate DemarsTeam
Timothy I. MitchellTeam

Everyone who backed them

RA Capital ManagementPrivate equity1round

Janus Henderson InvestorsPrivate equity1round

Eli LillyCorporate VC1round

NovartisVC firm1round

RTW Investments LLCGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 5 firms list Aktis Oncology as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.